U.S., July 23 -- ClinicalTrials.gov registry received information related to the study (NCT07720193) titled 'A Phase III Trial of LBL-024 Combined With Platinum-based Chemotherapy as First-line Treatment for Advanced EP-NEC' on July 17.
Brief Summary: This trial is a randomized, double-blind, placebo-controlled multicenter phase III clinical study aiming to evaluate the efficacy and safety of LBL-024 compared with placebo in combination with etoposide and cisplatin or carboplatin (EP or EC) for the first-line treatment of advanced EP-NEC patients.
Study Start Date: Aug. 22
Study Type: INTERVENTIONAL
Condition:
Advanced Extrapulmonary Neuroendocrine Carcinoma
Intervention:
DRUG: LBL-024 for Injection
Intravenous infusion
DRUG: Etopo...